Zearalenone (Z) hapten, zearalenone (Z) antigen, zearalenone (Z) antibody, preparation method and light-activated chemiluminescence quantitative detection kit

By designing zearidenone (Z) hapten and coupling it with carrier protein, the titer and sensitivity of the antibody are improved, and the problem of insufficient antibody detection sensitivity in existing detection methods is solved, achieving efficient and accurate corn red Mycene (Z) detection.

CN118994085AActive Publication Date: 2024-11-22GUIZHOU GUOXIN BIOTECHNOLOGY CO LTD

Patent Information

Application Number
CN202411091742.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-22
Estimated Expiration
2044-08-09

AI Technical Summary

Technical Problem

The existing ELISA kit of zearalenone (Z) and the photolass chemiluminescence rapid quantitative detection kit have problems such as insufficient detection sensitivity and low titer, resulting in low detection accuracy and efficiency.

Method used

A zearidenone (Z) hapten was designed to improve the immunogenicity of the antigen through the Fuker acylation reaction and the carrier protein coupling, and generate high-titer and high-sensitivity antibodies for photo-lass chemiluminescence quantification. In the test kit.

Benefits of technology

The accuracy and sensitivity of zearalenone (Z) detection has been improved, and the detection limit, false negative rate, false positive rate and instrument method compliance rate are all qualified. The detection steps are simple and have good practical value and industrial value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994085A_ABST
    Figure CN118994085A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of immunoassay, and provides a zearalenone (Z) hapten, an antigen, an antibody, a preparation method and a light-excited chemiluminescence quantitative detection kit. The hapten is obtained by taking cyclic carboxylic acid anhydride as a reactant and introducing an active group with n1 (n1 is more than or equal to 2 and less than or equal to 22) carbon atom carbon chains between two hydroxyl groups on a molecular benzene ring of zearalenone (Z) through Friedel-Crafts acylation reaction. After the hapten is coupled with carrier protein, the immunogenicity of the antigen can be enhanced, and an antibody with high titer and high sensitivity can be generated after the hapten is immunized by a host animal. Results of the embodiment show that after the zearalenone (Z) antigen is injected into a mouse for immunization, the titer of the generated antibody is 1: 5000, and IC50 is less than 10ppb / mL. When the zearalenone (Z) antigen and the zearalenone (Z) antibody are applied to light-excited chemiluminescence rapid quantitative detection of zearalenone (Z), the detection limit, the false negative rate and the like are qualified, the steps are simple, and the industrial value is high.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of immunoassay, and in particular to a zearalenone (Z) hapten, antigen, antibody and preparation method thereof, and a photoinduced chemiluminescence quantitative detection kit. Background Art

[0002] Zearalenone (Z) is a fungal toxin produced by mildew. It is a secondary metabolite produced by fungi. From corn, wheat, peanuts, to fruits, seasonings, Chinese medicinal materials, feed, and milk, mycotoxins are almost everywhere in our production and life. Zearalenone (Z) is very harmful to breeding livestock and poultry, often resulting in a breeding base failing to recover to its original level within a year, and causing a large area of ​​quality decline. It can be said that the problem of fungal toxin contamination in grain and oil products has become an important hidden danger to my country's food security and food safety, seriously endangering people's health and economic development.

[0003] The current rapid food safety testing products are divided into two types according to their properties: qualitative and quantitative testing. Qualitative products are mainly colloidal gold test strips, and quantitative products mainly include ELISA kits, fluorescent quantitative test strips, PCR detection kits, conventional chemiluminescence kits, etc. Qualitative products can only be used for qualitative analysis, and the products are greatly affected by different food matrices (color depth), and the qualitative test results are relatively meaningless for food safety supervision; while quantitative detection products such as ELISA kits, PCR test kits, and conventional chemiluminescence kits are relatively complex to operate, take a long time to detect, have relatively high costs for instruments and consumables, and have relatively high requirements for operators; fluorescent quantitative test strips are similar to colloidal gold qualitative test strips in that they are simple and fast to operate, but because of the principle of immunochromatography technology, the test results have poor parallelism and large errors; the currently used fluorescent quantitative test strips are mainly equipped with single-channel detection equipment, so the detection efficiency is low, which will affect the detection efficiency for large-volume sample detection scenarios; photochemiluminescence technology is a new fourth-generation chemiluminescence technology. Since it is a homogeneous reaction platform, no separation system is required during the detection process. It has the advantages of no wash, low background, high sensitivity, good repeatability, simple operation and short time consumption, and multi-channel simultaneous detection and analysis equipment is designed to improve sample detection efficiency.

[0004] However, the current ELISA kits and photochemiluminescence rapid quantitative detection kits for zearalenone (Z) generally have problems such as insufficient antibody detection sensitivity and low titer. Summary of the invention

[0005] In view of this, the present invention provides a hapten, antigen, antibody and preparation method of zearalenone (Z) and a photochemiluminescence quantitative detection kit. The antigen obtained by coupling the hapten of zearalenone (Z) provided by the present invention with a carrier protein has high immunogenicity, and can produce antibodies with high titer and high sensitivity after immunization of a host animal, which is beneficial to improve the accuracy of detecting zearalenone (Z) by immunoassay.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] A zearalenone (Z) hapten having a structure shown in formula I:

[0008]

[0009] In formula I: 0≤n2≤20.

[0010] The present invention provides a method for preparing the zearalenone (Z) hapten described in the above scheme, comprising the following steps:

[0011] The zearalenone (Z), cyclic carboxylic acid anhydride and a catalyst are mixed for Friedel-Crafts acylation reaction to obtain the zearalenone (Z) hapten having the structure of formula I; the cyclic carboxylic acid anhydride is the anhydride of a straight-chain alkyl diacid, and the straight-chain alkyl diacid contains n1 carbon atoms, and n1 is 2 to 22.

[0012] Preferably, the temperature of the Friedel-Crafts acylation reaction is 80-85° C., and the reaction time is 2-3 hours; the molar ratio of zearalenone (Z), catalyst and glutaric anhydride is 1:2-2.5:1-1.2.

[0013] The present invention also provides a zearalenone (Z) antigen, comprising the zearalenone (Z) hapten described in the above scheme, and a carrier protein coupled to the zearalenone (Z) hapten.

[0014] Preferably, the carrier protein and the zearalenone (Z) hapten are coupled via amide bonds.

[0015] The present invention also provides a method for preparing zearalenone (Z) antigen, comprising the following steps:

[0016] The zearalenone (Z) hapten, coupling activator and polar solvent described in the above technical solution are mixed and activated to obtain an activated zearalenone (Z) hapten solution;

[0017] The activated zearalenone (Z) hapten solution and the buffer solution of the carrier protein are mixed to carry out a coupling reaction to obtain the zearalenone (Z) antigen.

[0018] The present invention also provides a zearalenone (Z) antibody, which is obtained by immunizing a host animal with the zearalenone (Z) antigen described in the above technical solution or the zearalenone (Z) antigen prepared by the preparation method described in the above technical solution.

[0019] The present invention also provides a test paper or a kit for detecting zearalenone (Z), which contains the zearalenone (Z) antibody described in the above technical solution.

[0020] Preferably, the kit is a photochemiluminescence quantitative detection kit; the reagents in the photochemiluminescence rapid quantitative detection kit include chemiluminescence detection reagents; the chemiluminescence detection reagents include oxygen-accepting microspheres labeled with zearalenone (Z) antibodies, biotin labeled with zearalenone (Z) antigens, and oxygen-donating microspheres labeled with streptavidin.

[0021] The present invention also provides the use of the zearalenone (Z) antibody described in the above technical solution or the test paper or kit described in the above technical solution in detecting zearalenone (Z) for non-diagnostic purposes.

[0022] The present invention provides a zearalenone (Z) hapten, the structural formula of which is shown in Formula I. The quality of an antibody depends on the structural characteristics of the hapten, and therefore the design of the hapten is of great importance. The present invention introduces an active group with a carbon chain of n2+2 carbon atoms in the middle position of two hydroxyl groups on the benzene ring of the zearalenone (Z) molecule, and the spacer arm of n2+2 carbon atoms can fully expose the molecule outside the protein after being coupled with a carrier protein, thereby enhancing the immunogenicity of the antigen, and after being immunized by a host animal, an antibody with high titer and high sensitivity can be produced, thereby improving the accuracy of the analysis and detection of zearalenone (Z).

[0023] The present invention also provides a method for preparing the zearalenone (Z) hapten described in the above scheme. The present invention introduces an active group with a carbon chain of n2+2 carbon atoms in the middle position of the two hydroxyl groups of the benzene ring on the zearalenone (Z) molecule through a Friedel-Crafts acylation reaction. The preparation method of the present invention can generate the zearalenone (Z) hapten in one step, has mild reaction conditions, simple operation, and easy post-processing.

[0024] The present invention also provides a zearalenone (Z) antigen, which is obtained by coupling the zearalenone (Z) hapten described in the above scheme with a carrier protein. After the zearalenone (Z) hapten provided by the present invention is coupled with a carrier protein, the antigen obtained has strong immunogenicity. The results of the embodiment show that after the zearalenone (Z) antigen of the present invention is injected into mice for immunization, the antibody titer generated is 1:5000, and the half inhibitory concentration (IC 50) is less than 10ppb / mL; when the zearalenone (Z) antigen and antibody obtained by the present invention are applied to the rapid quantitative detection of zearalenone (Z) by photoinduced chemiluminescence, the four dimensions of detection limit, false negative rate, false positive rate and instrument method compliance rate are all qualified, and the detection steps are simple, which has good practical value and industrial value. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 This is a schematic diagram of the product composition of the photochemiluminescence rapid quantitative detection kit of the present invention, Figure 1 Middle: 1-sample well, 2-foam packaging, 3-R1, 4-R2, 5-R3.

[0026] Figure 2 This is the hydrogen nuclear magnetic resonance spectrum of the zearalenone (Z) hapten prepared in Example 1 of the present invention. DETAILED DESCRIPTION

[0027] The present invention provides a zearalenone (Z) hapten having a structure shown in Formula I:

[0028]

[0029] In formula I: 0≤n2≤20.

[0030] In the present invention, n2 represents the number of methylene groups, specifically a positive integer of 0 to 20, preferably 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, more preferably 2 to 6, and even more preferably 3.

[0031] The present invention also provides a method for preparing the zearalenone (Z) hapten described in the above scheme, comprising the following steps:

[0032] The zearalenone (Z), cyclic carboxylic acid anhydride and a catalyst are mixed for Friedel-Crafts acylation reaction to obtain the zearalenone (Z) hapten having the structure of formula I; the cyclic carboxylic acid anhydride is the anhydride of a straight-chain alkyl diacid, and the straight-chain alkyl diacid contains n1 carbon atoms, and n1 is 2 to 22.

[0033] In the present invention, the synthesis route of the compound having the structure shown by the zearalenone (Z) hapten is shown in Chemical Reaction Formula 1:

[0034]

[0035] In the present invention, the cyclic carboxylic acid anhydride is specifically the anhydride of a straight-chain alkyl diacid, the straight-chain alkyl diacid contains n1 carbon atoms (including the carbon atoms in the carboxyl group), n1 is 2 to 22, and the relationship between n2 and n1 is: n2 = n1-2; specifically, the cyclic carboxylic acid anhydride is preferably oxalic anhydride, malonic anhydride, succinic anhydride, maleic anhydride, glutaric anhydride or adipic anhydride, more preferably glutaric anhydride.

[0036] In the present invention, the temperature of the Friedel-Crafts acylation reaction is preferably 80-85°C; the reaction time is preferably 2-3h; the molar ratio of the zearalenone (Z), the catalyst and the cyclic carboxylic acid anhydride is preferably 1:2-2.5:1-1.2, more preferably 1:2-2.2:1-1.1. The catalyst is preferably aluminum trichloride, and more preferably anhydrous aluminum trichloride. The reaction solvent of the Friedel-Crafts acylation reaction is preferably a chlorinated alkane, and more preferably 1,2-dichloroethane.

[0037] The present invention preferably places the catalyst in a dry container and dissolves it with a solvent, then adds a cyclic carboxylic acid anhydride to obtain a mixed solution of the cyclic carboxylic acid anhydride and the catalyst, and then slowly drips the zearalenone (Z) solution into the mixed solution of the cyclic carboxylic acid anhydride and the catalyst. After the dripping is completed, a Friedel-Crafts acylation reaction is performed; during the reaction, TLC is preferably used to monitor the progress of the reaction, and the reaction is performed until the raw material point disappears. In the present invention, the method for dissolving the catalyst is preferably: first placing the catalyst in a dry container, and then adding 1,2-dichloroethane dropwise at 0 to 5°C, stirring while dripping, and after the solvent is added, continuing to stir for 10 to 15 minutes to obtain a clear anhydrous aluminum chloride solution; after adding the cyclic carboxylic acid anhydride, it is preferably stirred again for 30 to 40 minutes. The method for preparing the zearalenone (Z) solution is preferably to dissolve zearalenone (Z) in 1,2-dichloroethane.

[0038] After the Friedel-Crafts acylation reaction is completed, the present invention preferably performs post-treatment on the obtained reaction solution, and the post-treatment preferably includes: cooling the reaction solution obtained by the Friedel-Crafts acylation reaction to room temperature, and then mixing it with ice cubes to obtain a mixed solution; extracting the mixed solution with ethyl acetate, washing the obtained organic phase and then distilling it under reduced pressure to obtain a residue, dissolving the residue with ethyl acetate and mixing it with silica gel, purifying it by dry column chromatography, collecting the main ultraviolet point components, and obtaining a light yellow oily liquid, which is the zearalenone (Z) hapten. In the present invention, the volume ratio of the ice cubes to the reaction liquid is preferably 1:1; the mixing of the ice cubes and the reaction liquid is preferably carried out under stirring conditions, and the stirring time is preferably 10 to 20 minutes; the number of extractions with ethyl acetate is preferably more than 1 time, more preferably 2 to 3 times, and when the number of extractions is greater than 1 time, it is preferred to combine the organic phases obtained by multiple extractions; the volume of ethyl acetate used for each extraction is preferably 1 / 2 of the volume of the reaction liquid; the washing preferably includes washing with saturated brine and washing with deionized water, and the number of washings with saturated brine is preferably 3 to 4 times; when mixing the sample with silica gel, it is preferred to use silica gel with a mass twice that of the residue for mixing the sample.

[0039] The present invention also provides a zearalenone (Z) antigen, comprising the zearalenone (Z) hapten described in the above scheme, and a carrier protein coupled to the zearalenone (Z) hapten; the carrier protein and the zearalenone (Z) hapten are preferably coupled by amide bond coupling; and 45 to 50 hapten molecules are preferably coupled to one carrier protein molecule.

[0040] In the present invention, the carrier protein is preferably ovalbumin (OVA); when the carrier protein is ovalbumin, the structure of the zearalenone (Z) antigen is shown in Formula II:

[0041]

[0042] In formula II: 0≤n2≤20.

[0043] In the present invention, when the carrier protein is preferably ovalbumin (OVA), the zearalenone (Z) antigen is specifically zearalenone (Z) coating antigen.

[0044] In the present invention, the carrier protein is preferably bovine serum albumin (BSA); when the carrier protein is bovine serum albumin, the structure of the zearalenone (Z) antigen is shown in Formula III:

[0045]

[0046] In formula III: 0≤n2≤20.

[0047] In the present invention, when the carrier protein is preferably bovine serum albumin (BSA), the zearalenone (Z) antigen is specifically a zearalenone (Z) immunogen.

[0048] The present invention also provides a method for preparing the zearalenone (Z) antigen described in the above scheme, comprising the following steps:

[0049] The zearalenone (Z) hapten, coupling activator and polar solvent described in the above technical solution are mixed and activated to obtain an activated zearalenone (Z) hapten solution;

[0050] The activated zearalenone (Z) hapten solution and the buffer solution of the carrier protein are mixed to carry out a coupling reaction to obtain the zearalenone (Z) antigen.

[0051] In the present invention, when the carrier protein is preferably ovalbumin (OVA), the synthesis route of the zearalenone (Z) antigen is as shown in Chemical Reaction Formula 2:

[0052]

[0053] When the carrier protein is preferably bovine serum albumin (BSA), the synthesis route of the zearalenone (Z) antigen is as shown in Chemical Reaction Formula 3:

[0054]

[0055] The present invention mixes the zearalenone (Z) hapten, coupling activator and polar solvent described in the above scheme for activation to obtain an activated zearalenone (Z) hapten solution. In the present invention, the polar solvent is preferably one or two of 1,4-dioxane, acetone, DMF and DMSO. The coupling activator is preferably one or more of tri-n-butylamine, isobutyl chloroformate, dicyclohexylcarbodiimide (DCC) and N-hydroxysuccinimide (NHS).

[0056] In the present invention, when the carrier protein is preferably ovalbumin (OVA), the polar solvent is preferably 1,4-dioxane, and the dosage ratio of the zearalenone (Z) hapten and the polar solvent is preferably 10 mg: 1 mL; the coupling activator is preferably tri-n-butylamine and isobutyl chloroformate; the molar ratio of the zearalenone (Z) hapten, tri-n-butylamine and isobutyl chloroformate is preferably 1:2-2.2:1-1.2; the activation temperature is preferably room temperature, and the time is preferably 12-16 hours. In a specific embodiment of the present invention, it is preferred to first dissolve the hapten in a polar solvent, then add tri-n-butylamine, and then add isobutyl chloroformate under ice bath conditions; after the addition of isobutyl chloroformate is completed, it is preferably reacted in an ice bath for 0.5-1 hour, and then the activation reaction is carried out at room temperature.

[0057] In the present invention, when the carrier protein is preferably bovine serum albumin (BSA), the specific process conditions of the activation are the same as when the carrier protein is ovalbumin (OVA), and it is only necessary to replace OVA with BSA, which will not be repeated here.

[0058] In the present invention, in the activated zearalenone (Z) hapten solution, the zearalenone (Z) hapten exists in the form of zearalenone (Z) hapten activated ester; the hapten activated ester is a key intermediate for synthesizing two antigens, and the structure of the zearalenone (Z) hapten activated ester is shown in Formula IV:

[0059]

[0060] After obtaining the activated zearalenone (Z) hapten solution, the present invention mixes the activated zearalenone (Z) hapten solution and the buffer solution of the carrier protein for coupling reaction to obtain the zearalenone (Z) antigen. In the present invention, the concentration of the carrier protein in the buffer solution of the carrier protein is preferably 10-12 mg / mL; the buffer solution of the carrier protein is specifically obtained by dissolving the carrier protein in a buffer solution; the buffer solution is preferably a disodium hydrogen phosphate-sodium dihydrogen phosphate (PB) buffer solution, the concentration of the PB buffer solution is preferably 0.05-0.1 mol / L, and the pH value is preferably 8.0-8.5; the molar ratio of the carrier protein to the activated ester of the zearalenone (Z) hapten is preferably 1:45-50; in a specific embodiment of the present invention, the activated zearalenone (Z) hapten solution is preferably added dropwise to the buffer solution of the carrier protein; the temperature of the coupling reaction is preferably room temperature, and the time is preferably 6-8 hours.

[0061] After the coupling reaction is completed, the present invention preferably centrifuges the obtained reaction solution and dialyzes the obtained supernatant to obtain the zearalenone (Z) antigen. The dialysate used for the dialysis is preferably a PB buffer, and the pH of the PB buffer is preferably 6.9-7.2; the molecular weight cutoff of the dialysis bag for dialysis is preferably 8000-14000Da; the dialysis time is preferably 2-3 days, and when the carrier protein is BSA, the dialysis time is more preferably 3 days; the amount of the dialysis solution used each time is preferably 500-800mL; the dialysis solution is preferably replaced 2-3 times a day. After the dialysis is completed, it is preferred to collect the solution in the dialysis bag and aliquot it for frozen storage for later use.

[0062] The present invention also provides a zearalenone (Z) antibody, which is obtained by immunizing a host animal with the zearalenone (Z) antigen described in the above technical scheme or the zearalenone (Z) antigen prepared by the preparation method described in the above technical scheme; the host animal is preferably a mouse; the present invention has no special requirements for the immunization method, and a method well known to those skilled in the art can be used; in a specific embodiment of the present invention, it is preferred to use an incomplete Freund's adjuvant to emulsify the zearalenone (Z) immunogen diluent before immunizing the host animal; the diluent used for the zearalenone (Z) immunogen diluent is preferably a sterilized 1wt% sodium chloride solution.

[0063] In a specific embodiment of the present invention, the process for preparing the zearalenone (Z) antibody is preferably as follows:

[0064] Immunizing a host animal with an emulsified zearalenone (Z) immunogen to obtain an immune animal, performing a serum test on the immune animal using an ELISA method, and preparing a monoclonal antibody according to a monoclonal antibody preparation method when serum parameters meet the requirements;

[0065] Extracting spleen cells from the immunized animal and fusing them with myeloma cells of the same family to obtain fused cells;

[0066] Performing hybridoma screening on the fusion cells;

[0067] The limiting dilution method is used for cloning and culture of hybridoma cells, and the immunological method is used to screen out positive hybridoma cells that can produce the required monoclonal antibodies, and then clone and expand them.

[0068] The present invention also provides a test paper or kit for detecting zearalenone (Z), which contains the zearalenone (Z) antibody described in the above scheme. In the present invention, the kit is preferably a photoinduced chemiluminescence rapid quantitative detection kit; the photoinduced chemiluminescence rapid quantitative detection kit includes a chemiluminescence detection reagent; the chemiluminescence detection reagent preferably includes oxygen accepting microspheres labeled with zearalenone (Z) antibody, biotin labeled with zearalenone (Z) antigen, and oxygen supplying microspheres labeled with streptavidin. In the present invention, the oxygen acceptor microspheres labeled with zearalenone (Z) antibody are obtained by labeling the zearalenone (Z) antibody of the present invention with oxygen acceptor microspheres. The present invention has no special requirements for the labeling method and the type of oxygen acceptor microspheres, and those familiar to those skilled in the art can be used; the biotin labeled with zearalenone (Z) antigen is obtained by labeling the zearalenone (Z) antigen of the present invention (in a specific embodiment of the present invention, preferably zearalenone (Z) coating source) with biotin. The present invention has no special requirements for the labeling method and biotin, and those familiar to those skilled in the art can be used; the oxygen supply microspheres labeled with streptavidin are obtained by labeling the oxygen supply microspheres with streptavidin, and the oxygen supply microspheres labeled with streptavidin are microspheres familiar to those skilled in the art. In a specific embodiment of the present invention, the oxygen acceptor microspheres labeled with zearalenone (Z) antibody, the biotin labeled with zearalenone (Z) antigen, and the oxygen supply microspheres labeled with streptavidin are reagents R1, R2, and R3, respectively.

[0069] In the present invention, the photochemiluminescence rapid quantitative detection kit preferably also includes a sample plate and foam packaging; the sample plate preferably has a sample well in the center, the sample plate is preferably square in shape, the material is preferably PP material, and the color is preferably black; the sample well is preferably round in shape, and the material of the sample well is preferably PVC microporous plate; the foam packaging is preferably a foam pad, and the surface of the foam pad is die-cut with corresponding size holes according to the size of the reagent bottle for fixing the photochemiluminescence detection reagents R1, R2 and R3. In the present invention, the product composition of the photochemiluminescence rapid quantitative detection kit is as follows Figure 1 As shown, Figure 1 Middle: 1-sample well, 2-foam packaging, 3-R1, 4-R2, 5-R3.

[0070] In the present invention, when the photoluminescence rapid quantitative detection kit is used for detection, the specific detection method is preferably: add the sample test solution, reagent R1, reagent R2 and reagent R3 to the sample wells respectively; place the sample wells in the corresponding positions of the photoluminescence detector, detect the light signal value, and calculate the content of zearalenone (Z) in the sample test solution according to the corresponding relationship between different light signal values ​​and the concentration of the standard. In a specific embodiment of the present invention, it is preferred to set the detection sample information on the instrument display screen of the photoluminescence detector, and wait for the instrument to automatically read the results.

[0071] In the present invention, the preparation method of the sample to be tested liquid is preferably: the sample is crushed and then sieved to obtain sample powder; the sample powder and the extractant are mixed and vortexed to obtain a sample extraction suspension; the sample extraction suspension is centrifuged or allowed to stand, and the supernatant is taken; the supernatant is mixed with a sample diluent to obtain the sample to be tested liquid; the crushing is preferably performed in a crusher, and the vortexing and centrifugation are preferably performed in a centrifuge tube; the extractant is preferably an ethanol-water solution; the volume ratio of ethanol to water in the ethanol-water solution is preferably 1:4, and the amount ratio of the sample powder to the extractant is preferably 1g:(5-10)mL; the sample diluent is preferably a PB buffer solution, and the pH of the PB buffer solution is preferably 7.2, and the concentration is preferably 0.05mol / L; the volume ratio of the supernatant to the sample diluent is preferably 1:2 to 1:5.

[0072] In the present invention, the photoinduced chemiluminescence rapid quantitative detection kit is preferably used to quantitatively detect the content of zearalenone (Z) in feed raw materials or finished feeds; the feed raw materials preferably include corn, wheat, flour, wheat bran, soybean meal, peanut meal, rice bran meal, corn protein meal, corn germ meal, puffed corn, DDGS, sprayed corn husk, second meal or citric acid residue.

[0073] The present invention also provides the use of the zearalenone (Z) antibody described in the above scheme or the test paper or kit described in the above scheme in detecting zearalenone (Z) for non-diagnostic purposes; the method for detecting zearalenone (Z) is preferably an immunoassay, more preferably an ELLSA kit method or a photochemiluminescence method. The zearalenone (Z) antigen of the present invention is used to immunize mice, and the resulting antibody has high titer and high sensitivity. The application of the antibody in the detection of zearalenone (Z) can improve the accuracy and sensitivity of the detection method.

[0074] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0075] Example 1

[0076] Synthesis of Zearalenone (Z) Hapten

[0077] In a clean and dry 250mL round-bottom flask, add 5.99g of anhydrous aluminum chloride, add 62.5mL of 1,2-dichloroethane dropwise under stirring at 0℃, stir for 10min after the addition is complete, and when the solution is clear and there is no white smoke, add 2.64g of glutaric anhydride and stir for 30min. After 6.13g of zearalenone (Z) is fully dissolved in 32mL of 1,2-dichloroethane, slowly add dropwise to the reaction system, and after the addition is complete, reflux at 80℃ and monitor by TLC. After 2h of reaction, the raw material point disappears. Stop the reaction, cool the reaction solution to room temperature, pour into ice cubes frozen with 94.5mL deionized water, stir for 10min, extract twice with ethyl acetate, consume 47mL ethyl acetate each time, combine the organic phases, wash three times with saturated brine, consume 47mL saturated brine each time, wash once with 94mL deionized water, remove the solvent by vacuum distillation, dissolve the residue with 94mL ethyl acetate, mix with 24g silica gel, purify by dry column chromatography, collect the main ultraviolet point components, and obtain a light yellow oily liquid, which is the zearalenone (Z) hapten. After testing, the purity of the hapten is 96.7%. The product was tested by nuclear magnetic resonance, and the results are as follows: Figure 2 As shown, according to Figure 2 It can be seen that the product has the target structure.

[0078] Synthesis of Zearalenone (Z) Antigen

[0079] 1: Synthesis of Zearalenone (Z) Coating

[0080] 10 mg of hapten was dissolved in 1 mL of 1,4-dioxane, 6.48 mg of tri-n-butylamine was added, and 3.14 mg of isobutyl chloroformate was added under ice bath. After addition, the reaction was carried out for 0.5 h, and then the reaction was restored to room temperature for 12 h. 22.86 mg of OVA was weighed and dissolved in 1.2 mL of PB buffer (the concentration of PB buffer was 0.05 mol / L, pH = 8.0). After clarification, the prepared hapten activation solution was added dropwise. After addition, the reaction was carried out for 6 h at room temperature, and then the reaction solution was centrifuged, the supernatant was aspirated, and added to a dialysis bag with a molecular weight cutoff of 8000-14000 for 2 days. The dialysate was 0.02 mol / L, pH = 6.9 PB buffer. The dialysate was changed twice a day, and 500 mL of the dialysate was used each time. After the dialysis was completed, the solution in the dialysis bag was aspirated and aliquoted and frozen for later use.

[0081] 2: Synthesis of Zearalenone (Z) Immunogen

[0082] The other conditions were the same as those for the synthesis of the zearalenone (Z) coating, except that 22.86 mg OVA was replaced with 12.24 mg BSA.

[0083] Example 2

[0084] Synthesis of Zearalenone (Z) Hapten

[0085] In a clean and dry 50mL round-bottom flask, add 1.77g of anhydrous aluminum chloride, add 12.5mL of 1,2-dichloroethane dropwise at 5℃ with stirring, after the addition is complete, stir for 15min, after the solution is clear and there is no white smoke, add 0.73g of glutaric anhydride and stir for 35min, after 1.70g of zearalenone (Z) is fully dissolved in 6.25mL of 1,2-dichloroethane, slowly add dropwise to the reaction system, after the addition is complete, reflux at 85℃ and monitor by TLC. After 3h of reaction, the raw material point disappears. The reaction was stopped, the reaction solution was cooled to room temperature, poured into ice cubes frozen with 18.75 mL of deionized water, stirred for 20 min, extracted with ethyl acetate 3 times, consuming 9.38 mL of ethyl acetate each time, and the organic phases were combined, washed with saturated brine 4 times, consuming 9.38 mL of saturated brine each time, and washed once with 18.75 mL of deionized water, and the solvent was removed by vacuum distillation, dissolved with 18.75 mL of ethyl acetate, mixed with 6 g of silica gel, purified by dry column chromatography, and the main ultraviolet point components were collected to obtain a light yellow oily liquid, which was the zearalenone (Z) hapten. After testing, the purity of the hapten was 90.2%.

[0086] Synthesis of Zearalenone (Z) Antigen

[0087] 1: Synthesis of Zearalenone (Z) Coating

[0088] 15 mg of hapten was dissolved in 1.5 mL of 1,4-dioxane, 13.6 mg of tri-n-butylamine was added, and 5.25 mg of isobutyl chloroformate was added under ice bath. After addition, the reaction was carried out for 1 hour, and then the reaction was restored to room temperature for 15 hours. 32.2 mg of OVA was weighed and dissolved in 3 mL of PB buffer (the concentration of PB buffer was 0.08 mol / L, pH = 8.3). After clarification, the prepared hapten activation solution was added dropwise. After addition, the reaction was carried out for 7 hours at room temperature, and then the reaction solution was centrifuged, the supernatant was aspirated, and added to a dialysis bag with a molecular weight cutoff of 8000-14000 for 3 days. The dialysate was 600 mL, 0.04 mol / L, pH = 7.2 PB buffer, and the dialysate was changed 3 times a day. After the dialysis was completed, the solution in the dialysis bag was aspirated and aliquoted and frozen for later use.

[0089] 2: Synthesis of Zearalenone (Z) Immunogen

[0090] The other conditions are the same as those for the synthesis of the zearalenone (Z) coating source, except that 22.86 mg OVA is replaced with 18.37 mg BSA.

[0091] Example 3

[0092] Synthesis of Zearalenone (Z) Hapten

[0093] In a clean and dry 25mL round-bottom flask, add 0.33g of anhydrous aluminum chloride, and add 6.25mL of 1,2-dichloroethane dropwise at 3℃ with stirring. After the addition is complete, stir for 12min. When the solution is clear and there is no white smoke, add 0.133g of glutaric anhydride and stir for 40min. After 0.31g of zearalenone (Z) is fully dissolved in 3.125mL of 1,2-dichloroethane, slowly add dropwise to the reaction system. After the addition is complete, reflux at 85℃ and monitor by TLC. After 3h of reaction, the raw material point disappears. Stop the reaction, cool the reaction solution to room temperature, pour into ice cubes of the same volume as the reaction solution, stir for 15 minutes, extract with ethyl acetate for 3 times, consuming 4.69 mL of ethyl acetate each time, combine the organic phases, wash with saturated brine for 3 times, consuming 4.69 mL of saturated brine each time, and then wash once with 9.3 mL of deionized water, remove the solvent by vacuum distillation, dissolve in 9.3 mL of ethyl acetate, mix with 1.5 g of silica gel, purify by dry column chromatography, collect the main ultraviolet point components, and obtain a light yellow oily liquid, which is the zearalenone (Z) hapten.

[0094] Synthesis of Zearalenone (Z) Antigen

[0095] 1: Synthesis of Zearalenone (Z) Coating

[0096] 20 mg of hapten was dissolved in 2 mL of 1,4-dioxane, 16 mg of tri-n-butylamine was added, and 7.54 mg of isobutyl chloroformate was added under ice bath. After addition, the reaction was carried out for 40 min, and then the reaction was restored to room temperature for 14 h. 41.16 mg of OVA was weighed and dissolved in 4 mL of PB buffer (the concentration of PB buffer was 0.1 mol / L, pH = 8.5). After clarification, the prepared hapten activation solution was added dropwise. After addition, the reaction was carried out for 6.5 h at room temperature, and then the reaction solution was centrifuged, the supernatant was aspirated, and added to a dialysis bag with a molecular weight cutoff of 8000-14000 for 2.5 days. The dialysate was 800 mL, 0.03 mol / l, pH = 7.1 PB buffer. The dialysate was changed 3 times a day. After the dialysis was completed, the solution in the dialysis bag was aspirated and aliquoted and frozen for later use.

[0097] 2: Synthesis of Zearalenone (Z) Immunogen

[0098] The other conditions are the same as those for the synthesis of the zearalenone (Z) coating, except that 22.86 mg OVA is replaced with 24.49 mg BSA.

[0099] Test Example 1 ELISA test

[0100] Immunization of mice: 15 purebred BALB / c mice aged 4-6 weeks were selected and marked with different colors 1-5. Six 2mL syringes were used, 3 of which were used to absorb 0.5mL of incomplete Freund's adjuvant, and the other 3 were used to absorb 0.5mL of zearalenone (Z) immunogen diluted with sterilized 1% sodium chloride solution, with concentrations of 50μg, 100μg, and 200μg, respectively. After marking the numbers, the injection heads of an incomplete Freund's adjuvant syringe and an immunogen syringe were connected with an infusion tube (the length should be such that the two syringe heads can be connected together), and then the syringes were pushed back and forth by both hands until they were completely emulsified (emulsification was marked as white milky liquid inside, slight resistance could be felt during the pushing process, and small drops of water would not spread). During the emulsification process, it could not be stopped halfway until the emulsification was completed, otherwise it would not be emulsified. After the emulsification was completed, multiple injections were made subcutaneously (back and abdomen), and each mouse was injected with about 0.2ml. The same method is repeated every 2 weeks, and blood sampling tests are started after 3 times;

[0101] Blood collection method: Grab the mouse's neck scalp with the thumb, index finger and middle finger of the left hand, and fix the tail with the little finger and ring finger; gently press the eye skin to be removed to make the eyeball congested and protruding; insert a glass capillary vertically into the protruding part of the mouse's eyeball, and gently rotate it left and right until blood flows into the capillary (about 2 / 3 of the capillary), take out the blood in the capillary and blow it into a 0.5mL centrifuge tube (store at low temperature) with an ear washing bulb;

[0102] After blood collection, the samples were placed in a 37°C oven for 30 min, and then centrifuged in a low-temperature high-speed centrifuge (10,000 rpm) for 10 min to separate the serum for ELISA testing.

[0103] Monoclonal antibody preparation process:

[0104] Cell fusion: Mice are killed with carbon dioxide gas, the spleen is removed aseptically, and then squeezed and ground in a plate to prepare a spleen cell suspension. The prepared syngeneic myeloma cells are mixed with mouse spleen cells in a certain proportion, and the fusion promoter polyethylene glycol is added. Under the action of polyethylene glycol, various lymphocytes can fuse with myeloma cells to form hybridoma cells.

[0105] Selective culture: The purpose of selective culture is to screen fused hybridoma cells, and HAT selective culture medium is generally used. In HAT culture medium, unfused myeloma cells die because they lack hypoxanthine-guanine-phosphoribosyltransferase and cannot synthesize DNA using the salvage pathway. Although unfused lymphocytes have hypoxanthine-guanine-phosphoribosyltransferase, they cannot survive in vitro for a long time and gradually die. Only fused hybridoma cells can survive and proliferate in HAT culture medium because they have obtained hypoxanthine-guanine-phosphoribosyltransferase from spleen cells and have the characteristics of myeloma cells that can proliferate indefinitely.

[0106] Screening and cloning of hybridoma positive clones: Among the hybridoma cells grown in HAT medium, only a few are cells that secrete the predetermined specific monoclonal antibodies, so they must be screened and cloned. Usually, the limiting dilution method is used for cloning and culturing of hybridoma cells. A sensitive, rapid, and specific immunological method is used to screen out positive hybridoma cells that can produce the required monoclonal antibodies, and clone and expand them. After a comprehensive identification of the immunoglobulin type, subclass, specificity, affinity, epitope of the antigen recognized, and molecular weight of the monoclonal antibodies secreted, they are frozen in time.

[0107] Preparation of large quantities of monoclonal antibodies: Take Balb / c mice and first inject 0.5 ml of liquid paraffin or pristane intraperitoneally for pretreatment. After 1-2 weeks, inoculate hybridoma cells intraperitoneally. Hybridoma cells proliferate in the mouse peritoneal cavity and produce and secrete monoclonal antibodies. After about 1-2 weeks, the mouse abdomen can be seen to swell. Draw ascites with a syringe to obtain a large amount of monoclonal antibodies.

[0108] ELISA test of new synthetic antigens and preparation of antibodies technical parameters

[0109] 1. The reagent formula used is as follows:

[0110] Blocking solution (1L volume): 2.5g skim milk powder, 8g sodium chloride, 0.6g potassium dihydrogen phosphate, 5.8g disodium hydrogen phosphate, 50g sucrose, 0.9g potassium chloride, 0.5mL preservative, 50mL bovine serum, and the balance is water.

[0111] Enzyme dilute (16L): sodium chloride 128g, potassium dihydrogen phosphate 9.48g, disodium hydrogen phosphate 92.8g, glycerol 800mL, bovine serum 3200mL, preservative 12mL, water 12L.

[0112] Sample dilution (4 L): 23.38 g sodium chloride, 0.118 g potassium chloride, 3.48 g potassium dihydrogen phosphate, 2.19 g sodium dihydrogen phosphate, 20.64 g disodium hydrogen phosphate, 40 mL Triton, 1.5 mL preservative, and the balance is water.

[0113] Substrate A solution (100 mL): 0.48 g citric acid, 0.05 g urea peroxide, 90 mL glacial acetic acid, and the balance is water.

[0114] Substrate B solution (400 mL): 0.164 g citric acid, 0.2 g TMB hydrochloride, 4 mL N,N-dimethylformamide, 14 mL methanol, 160 μL 1 mol / L hydrochloric acid, and the balance water.

[0115] 20× concentrated washing liquid (40L): 2560g sodium chloride, 928g disodium hydrogen phosphate, 80g potassium dihydrogen phosphate, 1.44g potassium chloride, 12mL preservative, 800mL Tween 20, and the balance is water.

[0116] 2. The specific test methods are as follows:

[0117] (1) Antigen coating: dilute the zearalenone (Z) coating source to a ratio of 1K:2W using CB buffer. After dilution, add 100 μL / well into the ELISA microplate. Cover with a cover film and place at 37°C for coating for 2 h.

[0118] (2) Blocking: After coating, remove and discard the coating solution, then use washing working solution (20× concentrated washing solution diluted to 1×), 250 μL / well or wash once with a washing pot, soak for 30 seconds, discard and pat dry with absorbent paper or towel, add blocking solution 150 μL / well, place in a 37°C constant temperature incubator for reaction for 2 hours, remove and discard the blocking solution, pat dry for later use.

[0119] (3) Dilution of different standard concentrations: Use 0.02 mol / L PBS1 buffer to dilute the purchased 100 μg / mL high-standard zearalenone (Z) to 0 ppb (directly PBS1 buffer), 1 ppb / mL, 10 ppb / mL, and 100 ppb / mL.

[0120] (4) Dilution of enzyme-labeled secondary antibody working solution: Dilute the purchased enzyme-labeled secondary antigen solution to a concentration of 1:1K using enzyme dilution buffer.

[0121] (5) Dilution of serum or monoclonal antibody working solution: dilute the serum or prepared monoclonal antibody to a concentration of 1:1000, 1:5000, 1:20000, or 1:100000 using sample dilution buffer.

[0122] (6) Testing steps: Test according to the chessboard method. The specific steps are as follows:

[0123] 1) Add standard / sample: Add 50 μL of standard / sample to the corresponding microwells.

[0124] 2) Serum or monoclonal antibody working solution: add 50 μL / well of serum or monoclonal antibody working solution, gently shake to mix, cover the plate with cover film, and then react at 37°C in a dark environment for 30 minutes.

[0125] 3) Wash the plate and add enzyme-labeled secondary antibody working solution: Carefully peel off the cover film, shake off the liquid in the wells, add 250μL / well of washing working solution, wash thoroughly 4 to 5 times, with an interval of 10s each time, pour out the washing solution in the wells, pat dry with absorbent paper (the bubbles that are not removed after patting dry can be punctured with an unused gun tip), add 100μL / well of enzyme-labeled secondary antibody working solution, cover the plate with the cover film, and react at 37℃ in a dark environment for 30min.

[0126] 4) Washing the plate: Carefully peel off the cover film, shake off the liquid in the wells, add 250μL / well of washing working solution, wash thoroughly 4 to 5 times, with an interval of 10 seconds each time, pour out the washing solution in the wells, and pat dry with absorbent paper (air bubbles that are not removed after patting dry can be punctured with an unused pipette tip).

[0127] 5) Color development: Add 50 μL / well of substrate solution A and solution B, gently shake to mix, cover the plate with a cover film, and react at 37°C in a dark environment for 15 minutes.

[0128] 6) Determination: Add 50 μL / well of stop solution, gently shake to mix, set the microplate reader at 450 nm, and measure the OD value of each well.

[0129] When the maximum antibody dilution factor is about 2.0 under the condition that the relevant technical parameters are met, the maximum antibody dilution factor is the antibody titer.

[0130] The test results are shown in Tables 1 to 5.

[0131] Table 1 2 Serum test data after immunization

[0132]

[0133] Table 2 3 Serum test data after immunization

[0134]

[0135] Table 3 4 Serum test data after immunization

[0136]

[0137] Table 4 Whole serum test data

[0138]

[0139] Table 5 Preparation of monoclonal antibody test data

[0140]

[0141]

[0142] According to the data in Tables 1 to 3, it can be seen that with the increase in the number of immunizations, the concentration of zearalenone (Z) antibodies in the serum gradually increased; according to the data in Table 4, it can be seen that the concentration of zearalenone (Z) in the serum has basically reached 1:20000, the antigen concentration is 1:1000 or the serum concentration is 1:1000, the antigen concentration is 1:20000, IC 50 According to the results in Table 5, the titer of the prepared monoclonal antibody was 1:5000, and the half inhibitory concentration (IC 50 ) is less than 10ppb / mL.

[0143] Test Example 2

[0144] Photoluminescence rapid quantitative detection kit for zearalenone (Z) in cereal feed

[0145] A photoluminescence rapid quantitative detection kit for zearalenone (Z) in cereal feed, the product composition is as follows Figure 1 shown.

[0146] Its components and functions are shown in Table 6:

[0147] Table 6 Product composition and specifications

[0148]

[0149] Sample well: The outer square of the sample well is made of black PP material. It is mainly used to fix the middle sample well and put it into the photochemiluminescence detection instrument for result testing. The middle circular hole is a PVC microplate, which is mainly used to hold the sample to be tested and as a reaction container.

[0150] Foam packaging: The main material is foam pad, and the corresponding size holes are die-cut according to the size of the reagent bottle to fix the photochemiluminescence detection reagent (R1, R2, R3);

[0151] R1 reagent: oxygen acceptor microspheres labeled with zearalenone (Z) antibody (the oxygen acceptor microspheres were directly purchased from Beijing Kemei Biotechnology Co., Ltd., and the zearalenone (Z) antibody was the antibody obtained in Test Example 1);

[0152] R2 reagent: biotin for labeling zearalenone (Z) antigen (biotin is purchased directly from Sigma, and the zearalenone (Z) antigen is the zearalenone (Z) coating antigen prepared in Example 1);

[0153] R3 reagent: oxygen supply microspheres labeled with streptavidin (purchased directly from Beijing Kemei Biotechnology Co., Ltd.).

[0154] The relevant data of the zearalenone (Z) curve are shown in Table 7:

[0155] Table 7 Zearalenone curve

[0156] Standard concentration (ng / g) Absorbance value 0 79543 50 73538 150 65097 450 40056 900 11431

[0157] Calibration curve fitting equation: y = -75.12x + 77220, R 2 =0.99, where x is the concentration of eritheranone (Z) in ng / g, and y is the absorbance value.

[0158] Kit Performance

[0159] 1. Quantitative detection range: 25~800μg / kg

[0160] 2. Accuracy: 80%~120%

[0161] 3. Precision: CV ≤ 15%

[0162] 4. Detection time: 20 minutes (pre-treatment 5 minutes + incubation 15 minutes)

[0163] 5. Test specifications: 48 samples

[0164] Required equipment and consumables

[0165] (1) Photochemiluminescence immunoassay analyzer

[0166] (2) Crusher

[0167] (3) Pipette (20-200μL, 100-1000μL)

[0168] (4) Centrifuge

[0169] (5) Balance: Sensitivity 0.01g

[0170] (6) Timer

[0171] (7) Crusher

[0172] (8) 50mL centrifuge tube

[0173] (9) 2mL polystyrene centrifuge tube

[0174] Preparation before testing

[0175] 1. Return samples, reagents, and sample diluents to room temperature before use (reagent return time is about 30 minutes);

[0176] 2. Turn on the light-stimulated chemiluminescence detector and preheat it in advance in preparation for detection.

[0177] Sample preparation steps

[0178] 1. The sample should be restored to room temperature of 18-25℃ before testing;

[0179] 2. Sample processing method:

[0180] (1) The sample is fully crushed with a crusher (passed through a 20-mesh sieve);

[0181] (2) Take 2.0±0.05 g of the crushed sample into a 50 mL centrifuge tube, add 10 mL of sample extract (20% ethanol-water solution (v / v=1:4)), vortex for 1 min; put into a centrifuge and centrifuge at 3000 r / min;

[0182] (3) Take 200 μL of the supernatant and add it to 400 μL of the sample diluent. Vortex and mix to obtain the sample solution for testing.

[0183] Detection steps

[0184] 1. Add 100 μL of sample solution, 70 μL of reagent R1, 70 μL of reagent R2, and 70 μL of reagent R3 to the sample wells;

[0185] 2. Place the sample well in the corresponding position of the light-excited chemiluminescence detector, put the pipette tip in the corresponding position, and cover the machine;

[0186] 3. Set the test sample information on the instrument display screen and wait for the instrument to automatically read the test concentration value of zearalenone (Z).

[0187] Precautions

[0188] 1. The test strip box should be stored in a refrigerator at 4°C away from light. When taking reagents R1, R2, and R3, strong light should be avoided (the test strip box is the test kit);

[0189] 2. The operation should be carried out strictly according to the instructions. Do not mix different batches of reagent kits and sample diluents;

[0190] 3. The extracted sample solution should be tested within 4 hours. The diluted sample should be tested only once and should be diluted again when it needs to be tested again.

[0191] 4. Consumables such as pipette tips and centrifuge tubes cannot be reused to avoid cross contamination.

[0192] Storage and shelf life

[0193] 1. Storage conditions: Store the kit in a cool, dark and dry environment at 4°C;

[0194] 2. Validity period: This product is valid for 6 months.

[0195] Test Example 3

[0196] Verification of technical parameters of photoluminescence rapid quantitative detection kit for zearalenone (Z) in cereal feed

[0197] 1. Evaluation indicators

[0198] The evaluation indicators include four dimensions: detection limit, false negative rate, false positive rate, and instrument method compliance rate.

[0199] 2. Evaluation Method

[0200] (I) Detection limit

[0201] Take blank test samples from a batch of products and add 1 / 2 detection limit, 1 times detection limit, 2 times detection limit of the test drug standard, and blank samples, 10 copies each, and measure with the test products.

[0202] 2. False negative rate

[0203] 40 positive test samples (20 samples with the test product added at the detection limit and 20 samples with the test product added at a concentration twice the detection limit) were tested using three batches of the test product. The number of test-negative samples / total number of samples × 100% is the false negative rate (the average false negative rate of the three batches of products).

[0204] False positive rate

[0205] 40 negative samples (20 negative blank samples of the test product and 20 samples with the test product added at a concentration of 1 / 2 the detection limit) were tested using three batches of the test product. The false positive rate is the number of test positive samples / total number of samples × 100%.

[0206] (IV) Instrument and method compliance

[0207] One batch of products was used to measure 20 samples (10 negative / 10 positive) that had been tested using the national standard instrument method.

[0208] (V) Coefficient of variation

[0209] It includes at least 3 batches of product testing, and 10 positive samples (10 samples with the product to be tested spiked at the detection limit) are tested for each batch of product.

[0210] The detection method and sample pretreatment method in the above evaluation were carried out in accordance with Test Example 2.

[0211] 3. Evaluation Results

[0212] (I) Detection limit

[0213] Table 8 Detection limit determination results

[0214]

[0215]

[0216] Note: The qualified range of recovery rate of spiked concentration is 80%-120%.

[0217] 2. False negative rate

[0218] Table 9 False negative rate determination results

[0219]

[0220]

[0221] Note: The false negative rate must be less than 5%.

[0222] (III) False positive rate

[0223] Table 10 False positive rate determination results

[0224]

[0225] Note: The false positive rate must be less than 10%.

[0226] (IV) Instrument method compliance rate

[0227] Table 11 Instrument method compliance test results

[0228]

[0229] Note: The positive and negative conformity rate is not less than 90% to be qualified. The national standard number of the instrument national standard method reference is GB5009.209-2016 National Food Safety Standard Determination of Zearalenone in Food Method 1, and the rapid test product is the kit of the present invention.

[0230] (V) Coefficient of variation

[0231] Table 12 Coefficient of variation determination results

[0232]

[0233] Note: Coefficient of variation = standard deviation / mean value × 100%

[0234] It can be seen from the data in Tables 7 to 11 that the photochemiluminescence rapid quantitative detection kit for zearalenone (Z) of the present invention has a low minimum detection limit for zearalenone (Z), high sensitivity, and the false negative rate, false positive rate, and instrument method dimensions are all qualified.

[0235] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A hapten of zearalenone (Z), characterized in that: It has the structure shown in formula I: In formula I: 0≤n2≤20.

2. The method for preparing the zearalenone (Z) hapten according to claim 1, characterized in that: The following steps are involved: The zearalenone (Z), cyclic carboxylic acid anhydride and a catalyst are mixed for Friedel-Crafts acylation reaction to obtain the zearalenone (Z) hapten having the structure of formula I; the cyclic carboxylic acid anhydride is the anhydride of a straight-chain alkyl diacid, and the straight-chain alkyl diacid contains n1 carbon atoms, and n1 is 2 to 22.

3. The preparation method according to claim 2, characterized in that: The temperature of the Friedel-Crafts acylation reaction is 80-85°C and the reaction time is 2-3h; The molar ratio of zearalenone (Z), catalyst and glutaric anhydride is 1:2-2.5:1-1.

2.

4. A zearalenone (Z) antigen, characterized in that: It comprises the zearalenone (Z) hapten according to claim 1, and a carrier protein coupled to the zearalenone (Z) hapten.

5. The zearalenone (Z) antigen according to claim 4, characterized in that The coupling is an amide bond coupling.

6. The method for preparing the zearalenone (Z) antigen according to any one of claims 4 to 5, characterized in that: The following steps are involved: The zearalenone (Z) hapten according to claim 1, a coupling activator and a polar solvent are mixed and activated to obtain an activated zearalenone (Z) hapten solution; The activated zearalenone (Z) hapten solution and the buffer solution of the carrier protein are mixed to carry out a coupling reaction to obtain the zearalenone (Z) antigen.

7. A zearalenone (Z) antibody, characterized in that: The method is obtained by immunizing a host animal with the zearalenone (Z) antigen according to any one of claims 4 to 5 or the zearalenone (Z) antigen prepared by the preparation method according to claim 6.

8. A kit for detecting zearalenone (Z), characterized in that: Containing the zearalenone (Z) antibody according to claim 7.

9. The test paper or kit according to claim 8, characterized in that: The kit is a photoinduced chemiluminescence quantitative detection kit; the reagents in the photoinduced chemiluminescence rapid quantitative detection kit include chemiluminescence detection reagents; the chemiluminescence detection reagents include oxygen accepting microspheres marked with zearalenone (Z) antibodies, biotin marked with zearalenone (Z) antigens, and oxygen supplying microspheres marked with streptavidin.

10. Use of the zearalenone (Z) antibody according to claim 7 or the test paper or kit according to any one of claims 8 to 9 in detecting zearalenone (Z) for non-diagnostic purposes.

Citation Information

Patent Citations

  • Test paper strip for detecting zearalenone and application of test paper strip

    CN104849461A

  • Spinosad aglycone hapten, preparation method and application thereof

    CN112390776A

  • Zearalenone monoclonal antibody hybridoma cell strain and application thereof

    CN114214288A

  • Coix seed zearalenone enzyme-linked immunosorbent assay kit and method

    CN115724818A

Cited By

  • Deuterated zearalenone derivative compound, preparation method of deuterated zearalenone derivative compound, detection reagent and method for measuring content of zearalenone

    CN119684250A